Canaccord Genuity Group Cuts Quantum-Si (NASDAQ:QSI) Price Target to $1.00

Quantum-Si (NASDAQ:QSI) had its price objective decreased by Canaccord Genuity Group from $1.50 to $1.00 in a research report sent to investors on Wednesday morning,Benzinga reports. Canaccord Genuity Group currently has a hold rating on the stock.

Quantum-Si Trading Down 5.8 %

Shares of NASDAQ QSI opened at $0.73 on Wednesday. The stock has a fifty day moving average price of $0.85 and a 200 day moving average price of $1.11. Quantum-Si has a 12-month low of $0.70 and a 12-month high of $2.43. The company has a market cap of $104.54 million, a P/E ratio of -1.15 and a beta of 2.89.

Quantum-Si (NASDAQ:QSI) last posted its earnings results on Tuesday, November 12th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.03. Quantum-Si had a negative net margin of 3,968.84% and a negative return on equity of 36.96%. The business had revenue of $0.79 million for the quarter, compared to analysts’ expectations of $1.06 million. On average, sell-side analysts forecast that Quantum-Si will post -0.71 EPS for the current fiscal year.

Institutional Trading of Quantum-Si

Institutional investors have recently added to or reduced their stakes in the business. XTX Topco Ltd bought a new position in shares of Quantum-Si during the second quarter worth about $25,000. Public Employees Retirement System of Ohio bought a new stake in Quantum-Si in the 1st quarter valued at about $27,000. Bleakley Financial Group LLC acquired a new position in Quantum-Si during the 1st quarter valued at about $28,000. SG Americas Securities LLC bought a new position in Quantum-Si in the 3rd quarter worth about $53,000. Finally, Virtu Financial LLC bought a new position in Quantum-Si in the 1st quarter worth about $98,000. Institutional investors own 39.90% of the company’s stock.

Quantum-Si Company Profile

Quantum-Si incorporated, a life sciences company, engages in the development of single-molecule detection platform to enable Next Generation Protein Sequencing (NGPS). The company's platform is comprised of the Platinum NGPS instrument; the Platinum Analysis Software service; and reagent kits and semiconductor chips for use with its instruments.